Recent advances in visualizing Alzheimer's plaques by magnetic resonance imaging

Current Medical Imaging Reviews

Volumn 5, Issue 1, 2009, Pages 2-9

  Braakman, Niels ^a   van Buchem, Mark A ^b   Schliebs, Reinhard ^c   de Groot, Huub J M ^a   Alia, A ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Alzheimer's disease (AD); Amyloid plaque imaging; Longitudinal study; Magntic resonance imaging (MRI); Transgenic mouse

Indexed keywords

AMYLOID BETA PROTEIN; FLUORINE; GADOLINIUM; IRON; LIGAND; MANNITOL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

AGE; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN MAPPING; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DRUG PENETRATION; EARLY DIAGNOSIS; EX VIVO STUDY; HIPPOCAMPUS; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; IN VIVO STUDY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PRIORITY JOURNAL; RELAXATION TIME; REVIEW; SENILE PLAQUE; SENSITIVITY ANALYSIS;

EID: 65949092535     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340509787354741     Document Type: Review

References (39)

1. Khachaturian ZS. Diagnosis of Alzheimer'sdisease. ArchNeurol 1985; 42:1097-105.
2. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: A look to the future. Radiology 2003; 226: 315-36.
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Phys Rev 2001; 81: 741-66.
4. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005; 108: 193-214.
5. Maggio JE, Mantyh PW. Brain amyloid - a physicochemical perspective. Brain Pathol 1996; 6: 147-62.
6. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A-beta-42(43) and A-beta-40 in senile plaques with end specific A-beta monoclonals: evidence that an initially deposited species as A-beta-42(43). Neuron 1994; 13:45-53.
7. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991;12: 295-312.
8. Huddleston DE, Small SA. Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI. Nat Clin Pract Neurol 2005; 1:96-105.
9. Hardy J, Selkoe DJ. Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
10. Jack CR, Marjanska M, Wengenack TM, et al. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: A new tool in Alzheimer's disease research. Neuroscientist 2007; 13: 38-48.
11. Braak H and Braak E. Frequency of stages of Alzheimer-related leisions in different age catogories. Neurobiol Aging 1997; 18: 351-7.
12. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatr 2002;10:24-35.
13. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
14. Sair HI, Doraiswamy PM, Petrella JR. In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 2004; 46: 93-104.
15. Fagan AM, Minun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A-β42 in humans. Ann Neurol 2006; 59: 512-9.
16. Kantarci K, Jack CR. Neuroimaging in Alzheimer disease: An evidence-based review. Neuroimaging Clin N Am 2003; 13: 197-205.
17. Wengenack TM, Jack CR, Garwood M, Poduslo JF. MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice. Eur J Nucle Med Mol Imaging 2008; 35: S82-88.
18. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson A. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci U S A 1999; 96: 14079-84.
19. 2*-weighted MR microscopic images. NMR Biomed 2002; 15: 197-203.
20. Zhang J, Yarowsky P, Gordon MN, et al. Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med 2004; 51: 452-7.
21. Jack CR, Garwood M, Wengenack TM, et al. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 2004; 52: 1263-71.
22. Dhenain M, Delatour B, Walczak C, Volk A. Passive staining: A novel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease. Magn Reson Med 2006; 55: 687-93.
23. Poduslo JF, Wengenack TM, Curran GL, et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002; 11: 315-29.
24. Lee SP, Falangola MF, Nixon RA, Duff K, Helpern JA. Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med 2004; 52: 538-44.
25. Faber C, Zahneisen B, Tippmann F, Schroeder A, Fahrenholz F. Gradient-echo and CRAZED imaging for minute detection of Alzheimer plaques in an APP(V717I) × ADAM10-dn mouse model. Magn Reson Med 2007; 57: 696-703.
26. Wadghiri YZ, Sigurdsson EM, Sadowski M, et al. Detection of Alzheimer's amyloid in Transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003;50: 293-302.
27. 1H MRI detection of amyloid betaplaques in vivo. Nat Neurosci 2005; 8: 527-33.
28. Jack CR, Wengenack TM, Reyes DA, et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 2005; 25: 10041-48.
29. Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van der Linden A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med 2005; 53: 607-13.
30. Borthakur A, Gur T, Wheaton AJ, et al. In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J Magn Reson Imaging 2006; 24: 1011-17.
31. Braakman N, Matysik J, van Duinen SG, et al. Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 2006; 24(3): 530-6.
32. Hennig J, Nauerth A, Friedburg H. Rare Imaging - A Fast Imaging Method For Clinical Mr. Magn Reson Med 1986; 3: 823-33.
33. El Tayara NET, Volk A, Dhenain M, Delatour B. Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. Magn Reson Med 2007; 58: 179-84.
34. House MJ, St Pierre TG, McLean C. 1.4T study of proton magnetic relaxation rates, iron concentrations, and plaque burden in Alzheimer's disease and control postmortem brain tissue. Magn Reson Med 2008; 60: 41-52.
35. Rak M, Bigio MRD, Mai S, Westaway D, Gough K. Dense-core and diffuse Abeta plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy. Biopolymers 2007; 87: 207-17.
36. McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genetics 2006; 22: 281-9.
37. Sasaki A, Shoji M, Harigaya Y, et al. Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament typed, dystrophic neurites. Virchows Arch 2002; 441: 358-67.
38. 2 changes in mouse models of Alzheimer's disease. NMR Biomed 2007; 20: 343-51.
39. Speck O, Weigel M. Optimization of hyper TSE at 7T for efficient T2-weighted imaging. Proc Intl Soc Mag Reson Med 2008; 16: 1333.